BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15690133)

  • 1. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
    Tang BN; Sadeghi N; Branle F; De Witte O; Wikler D; Goldman S
    J Neurooncol; 2005 Jan; 71(2):161-8. PubMed ID: 15690133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
    Esparragosa Vazquez I; Ndiaye M; Di Stefano AL; Younan N; Larrieu-Ciron D; Seyve A; Picart T; Meyronet D; Boutet C; Vassal F; Carpentier C; Figarella-Branger D; Dehais C; Forest F; Rivoirard R; Ducray F;
    Eur J Neurol; 2023 Sep; 30(9):2879-2883. PubMed ID: 37204066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
    J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.
    Diabira S; Rousselet MC; Gamelin E; Soulier P; Jadaud E; Menei P
    J Neurooncol; 2001 Oct; 55(1):45-50. PubMed ID: 11804282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of oligodendroglial tumours: current developments.
    van den Bent MJ
    Forum (Genova); 2000; 10(2):108-18. PubMed ID: 10875973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    Cairncross G; Macdonald D; Ludwin S; Lee D; Cascino T; Buckner J; Fulton D; Dropcho E; Stewart D; Schold C
    J Clin Oncol; 1994 Oct; 12(10):2013-21. PubMed ID: 7931469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W; van der Rijt CC; Dinjens WN; Sillevis Smitt PA; Wertenbroek AA; Bromberg JE; van Heuvel I; Kros JM; van den Bent MJ
    J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
    Lebrun C; Fontaine D; Bourg V; Ramaioli A; Chanalet S; Vandenbos F; Lonjon M; Fauchon F; Paquis P; Frenay M
    Eur J Neurol; 2007 Apr; 14(4):391-8. PubMed ID: 17388986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
    BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
    Macdonald DR; Gaspar LE; Cairncross JG
    Ann Neurol; 1990 May; 27(5):573-4. PubMed ID: 2360797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
    Glass J; Hochberg FH; Gruber ML; Louis DN; Smith D; Rattner B
    J Neurosurg; 1992 May; 76(5):741-5. PubMed ID: 1564535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
    J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
    van den Bent MJ; Kros JM; Heimans JJ; Pronk LC; van Groeningen CJ; Krouwer HG; Taphoorn MJ; Zonnenberg BA; Tijssen CC; Twijnstra A; Punt CJ; Boogerd W
    Neurology; 1998 Oct; 51(4):1140-5. PubMed ID: 9781544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
    Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
    Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Zander T; Nettekoven W; Kraus JA; Pels H; Ko YD; Vetter H; Klockgether T; Schlegel U
    J Neurol; 2002 Aug; 249(8):1055-7. PubMed ID: 12195453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.